- Conditions
- Stroke, Secondary Prevention
- Interventions
- optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 5,390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 110
- States / cities
- Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–31
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Plantar Fasciitis, Chronic, Plantar Fasciitis
- Interventions
- Lipiodol
- Device
- Lead sponsor
- Joint & Vascular Institute
- Industry
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Libertyville, Illinois
- Conditions
- Arterial Embolization, Other Surgical Procedures, Obesity
- Interventions
- BeadBlock 300 - 500 Micron, Left Gastric Artery Embolization
- Device · Procedure
- Lead sponsor
- Dayton Interventional Radiology
- Other
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
- Drug · Other · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 24
- States / cities
- Costa Mesa, California • La Jolla, California • Orange, California + 19 more
- Conditions
- Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
- Interventions
- Embospheres Microspheres
- Device
- Lead sponsor
- Keith Pereira, MD:
- Other
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE), Lenvatinib
- Drug · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 9 more